Researchers successfully scaled up production of SMNP, a next-generation vaccine adjuvant combining saponin and MPLA, from laboratory to clinical manufacturing levels. The team achieved a 100-fold increase in production scale while maintaining particle consistency, safety, and potency. This breakthrough enables clinical trials of a promising adjuvant that could enhance vaccine effectiveness against complex pathogens and emerging diseases.
